Literature DB >> 15949657

Manual for the Extrapyramidal Symptom Rating Scale (ESRS).

Guy Chouinard1, Howard C Margolese.   

Abstract

The Extrapyramidal Symptom Rating Scale (ESRS) was developed to assess four types of drug-induced movement disorders (DIMD): Parkinsonism, akathisia, dystonia, and tardive dyskinesia (TD). Comprehensive ESRS definitions and basic instructions are given. Factor analysis provided six ESRS factors: 1) hypokinetic Parkinsonism; 2) orofacial dyskinesia; 3) trunk/limb dyskinesia; 4) akathisia; 5) tremor; and 6) tardive dystonia. Two pivotal studies found high inter-rater reliability correlations in both antipsychotic-induced movement disorders and idiopathic Parkinson disease. For inter-rater reliability and certification of raters, >or=80% of item ratings of the complete scale should be +/-1 point of expert ratings and >or=70% of ratings on individual items of each ESRS subscale should be +/-1 point of expert ratings. During a cross-scale comparison, AIMS and ESRS were found to have a 96% (359/374) agreement between TD-defined cases by DSM-IV TD criteria. Two recent international studies using the ESRS included over 3000 patients worldwide and showed an incidence of TD ranging from 10.2% (2000) to 12% (1998). ESRS specificity was investigated through two different approaches, path analyses and ANCOVA PANSS factors changes, which found that ESRS measurement of drug-induced EPS is valid and discriminative from psychiatric symptoms.

Entities:  

Mesh:

Year:  2005        PMID: 15949657     DOI: 10.1016/j.schres.2005.02.013

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  93 in total

1.  Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment.

Authors:  Ina Giegling; Antonio Drago; Martin Schäfer; Annette M Hartmann; Thomas Sander; Mohammad Reza Toliat; Hans-Jürgen Möller; Diana De Ronchi; Hans H Stassen; Dan Rujescu; Alessandro Serretti
Journal:  Psychopharmacology (Berl)       Date:  2010-11-16       Impact factor: 4.530

2.  Self-Evaluation of Negative Symptoms: A Novel Tool to Assess Negative Symptoms.

Authors:  Sonia Dollfus; Cyril Mach; Rémy Morello
Journal:  Schizophr Bull       Date:  2015-11-12       Impact factor: 9.306

Review 3.  Physical Health and Drug Safety in Individuals with Schizophrenia.

Authors:  Tamara Pringsheim; Martina Kelly; Doug Urness; Michael Teehan; Zahinoor Ismail; David Gardner
Journal:  Can J Psychiatry       Date:  2017-07-18       Impact factor: 4.356

4.  Drug-induced parkinsonism.

Authors:  Frandy Susatia; Hubert H Fernandez
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.598

Review 5.  Tardive Dyskinesia: Treatment Update.

Authors:  Divya Arya; Tarannum Khan; Adam J Margolius; Hubert H Fernandez
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-16       Impact factor: 5.081

6.  Prolactin, flupenthixol decanoate and first episode schizophrenia - clinical and laboratory correlates.

Authors:  Mari Retief; Bonginkosi Chiliza; Lebogang Phahladira; Robin Emsley; Laila Asmal
Journal:  Metab Brain Dis       Date:  2019-08-17       Impact factor: 3.584

7.  A Neural Signature of Parkinsonism in Patients With Schizophrenia Spectrum Disorders: A Multimodal MRI Study Using Parallel ICA.

Authors:  Robert C Wolf; Mahmoud Rashidi; Stefan Fritze; Katharina M Kubera; Georg Northoff; Fabio Sambataro; Vince D Calhoun; Lena S Geiger; Heike Tost; Dusan Hirjak
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

8.  Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia.

Authors:  Julie Eve Desmarais; Linda Beauclair; Lawrence Annable; Marie-Claire Bélanger; Theodore T Kolivakis; Howard C Margolese
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

9.  Mechanism-driven phase I translational study of trifluoperazine in adults with sickle cell disease.

Authors:  Robert E Molokie; Diana J Wilkie; Harriett Wittert; Marie L Suarez; Yingwei Yao; Zhongsheng Zhao; Ying He; Zaijie J Wang
Journal:  Eur J Pharmacol       Date:  2013-11-07       Impact factor: 4.432

10.  Predictors of community functioning in schizophrenia and substance use disorder patients.

Authors:  Simon Zhornitsky; Ginette Aubin; Joelle Desfossés; Elie Rizkallah; Tania Pampoulova; Olivier Lipp; Jean-Pierre Chiasson; Emmanuel Stip; Stéphane Potvin
Journal:  Community Ment Health J       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.